50 results
8-K/A
EX-10.1
ARAV
Aravive Inc
28 Oct 22
Other Events
4:05pm
or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges … ”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling
8-K
EX-10.1
ARAV
Aravive Inc
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges … ”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling
8-K
EX-10.1
ARAV
Aravive Inc
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including … or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment
8-K
EX-10.2
ARAV
Aravive Inc
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater … , contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating
8-K
EX-99.1
2211fvfg
8 Oct 20
Regulation FD Disclosure
5:01pm
8-K
EX-99.2
bn8y r29qft2jx
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
8-K
EX-99.2
87holtd
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
gwl0pt
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
eqv67cog13zoxkjxahqn
13 Jan 20
Other Events
8:06am
8-K
EX-99.1
aaabj gbh11gi9m
2 Dec 19
Other Events
5:18pm
8-K
EX-1.1
b108 wnyumdowyc1qy
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
8-K
EX-99.2
ym28hukkto24c2dym5wg
20 Nov 19
Other Events
7:05am
8-K
EX-99.1
73s01 8w8b6p7zbx
3 Oct 19
Other Events
7:15am
8-K
EX-99.1
dhv7ez589z c2ia63a
12 Aug 19
Other Events
7:05am